Literature DB >> 16847460

Treatment-resistant anxiety disorders.

A Bystritsky1.   

Abstract

Several epidemiological studies confirmed that Anxiety Disorders as a group are the most prevalent psychiatric conditions in the United States. The importance of these conditions is underlined by the fact that they cause significant disability, poor quality of life, alcohol and drug abuse. Anxiety disorders are treatable conditions and respond to the front-line interventions such as serotonin reuptake inhibitors and cognitive behavioral therapy. However, only about 60% of patients respond to those treatments to any significant degree. Many still have residual symptoms or stay treatment refractory. The group of anxiety patients that is resistant to the treatment has been shown to have very poor quality of life and have highest rate of suicidal attempts than any other disorders. Many biological, treatment specific and social factors are affecting treatment resistance. In this paper, we are attempting to review reasons for the treatment resistance. In addition, we would like to review current strategies that could be helpful in reducing treatment resistance and aiding people chronically suffering from these severe and disabling conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847460     DOI: 10.1038/sj.mp.4001852

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  61 in total

Review 1.  Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety.

Authors:  Xia Chen; Joop van Gerven; Adam Cohen; Gabriel Jacobs
Journal:  Acta Pharmacol Sin       Date:  2018-12-05       Impact factor: 6.150

2.  The cognitive-emotional brain: Opportunities [corrected] and challenges for understanding neuropsychiatric disorders.

Authors:  Alexander J Shackman; Andrew S Fox; David A Seminowicz
Journal:  Behav Brain Sci       Date:  2015       Impact factor: 12.579

3.  Worry is associated with impaired gating of threat from working memory.

Authors:  Daniel M Stout; Alexander J Shackman; Jeffrey S Johnson; Christine L Larson
Journal:  Emotion       Date:  2014-08-25

4.  Harnessing reconsolidation to weaken fear and appetitive memories: A meta-analysis of post-retrieval extinction effects.

Authors:  M Alexandra Kredlow; Leslie D Unger; Michael W Otto
Journal:  Psychol Bull       Date:  2015-12-21       Impact factor: 17.737

Review 5.  Dispositional negativity: An integrative psychological and neurobiological perspective.

Authors:  Alexander J Shackman; Do P M Tromp; Melissa D Stockbridge; Claire M Kaplan; Rachael M Tillman; Andrew S Fox
Journal:  Psychol Bull       Date:  2016-10-10       Impact factor: 17.737

6.  [Predictive factors of anxiety disorders].

Authors:  K Domschke
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

7.  Neuronal Deletion of Kmt2a/Mll1 Histone Methyltransferase in Ventral Striatum is Associated with Defective Spike-Timing-Dependent Striatal Synaptic Plasticity, Altered Response to Dopaminergic Drugs, and Increased Anxiety.

Authors:  Erica Y Shen; Yan Jiang; Behnam Javidfar; Bibi Kassim; Yong-Hwee E Loh; Qi Ma; Amanda C Mitchell; Venu Pothula; A Francis Stewart; Patricia Ernst; Wei-Dong Yao; Gilles Martin; Li Shen; Mira Jakovcevski; Schahram Akbarian
Journal:  Neuropsychopharmacology       Date:  2016-08-03       Impact factor: 7.853

8.  Contributions of the Central Extended Amygdala to Fear and Anxiety.

Authors:  Alexander J Shackman; Andrew S Fox
Journal:  J Neurosci       Date:  2016-08-03       Impact factor: 6.167

9.  Neurological and psychiatric diseases and their unique cognitive profiles: implications for nursing practice and research.

Authors:  David E Vance; Joan E Dodson; Jason Watkins; Bridgett H Kennedy; Norman L Keltner
Journal:  J Neurosci Nurs       Date:  2013-04       Impact factor: 1.230

10.  Neural mechanisms underlying heterogeneity in the presentation of anxious temperament.

Authors:  Alexander J Shackman; Andrew S Fox; Jonathan A Oler; Steven E Shelton; Richard J Davidson; Ned H Kalin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.